CN1443075A - 用于治疗念珠菌病的组合物和方法 - Google Patents

用于治疗念珠菌病的组合物和方法 Download PDF

Info

Publication number
CN1443075A
CN1443075A CN01812991A CN01812991A CN1443075A CN 1443075 A CN1443075 A CN 1443075A CN 01812991 A CN01812991 A CN 01812991A CN 01812991 A CN01812991 A CN 01812991A CN 1443075 A CN1443075 A CN 1443075A
Authority
CN
China
Prior art keywords
mice
candida albicans
infection
adjuvant
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01812991A
Other languages
English (en)
Chinese (zh)
Inventor
R·克兰西
G·庞
E·舒克罗拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CANDIVAX Pty Ltd
Original Assignee
CANDIVAX Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ8214A external-priority patent/AUPQ821400A0/en
Priority claimed from AUPQ8294A external-priority patent/AUPQ829400A0/en
Application filed by CANDIVAX Pty Ltd filed Critical CANDIVAX Pty Ltd
Publication of CN1443075A publication Critical patent/CN1443075A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN01812991A 2000-06-19 2001-06-19 用于治疗念珠菌病的组合物和方法 Pending CN1443075A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ8214 2000-06-19
AUPQ8214A AUPQ821400A0 (en) 2000-06-19 2000-06-19 Composition and methods for treatment of candidiasis
AUPQ8294A AUPQ829400A0 (en) 2000-06-22 2000-06-22 Compositions and methods for treatment of candidiasis
AUPQ8294 2000-06-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010200300A Division CN101862449A (zh) 2000-06-19 2001-06-19 用于治疗念珠菌病的组合物和方法

Publications (1)

Publication Number Publication Date
CN1443075A true CN1443075A (zh) 2003-09-17

Family

ID=25646360

Family Applications (2)

Application Number Title Priority Date Filing Date
CN01812991A Pending CN1443075A (zh) 2000-06-19 2001-06-19 用于治疗念珠菌病的组合物和方法
CN201010200300A Pending CN101862449A (zh) 2000-06-19 2001-06-19 用于治疗念珠菌病的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201010200300A Pending CN101862449A (zh) 2000-06-19 2001-06-19 用于治疗念珠菌病的组合物和方法

Country Status (10)

Country Link
US (1) US7655248B2 (https=)
EP (1) EP1303300B1 (https=)
JP (1) JP4933714B2 (https=)
KR (1) KR20030016298A (https=)
CN (2) CN1443075A (https=)
AT (1) ATE476987T1 (https=)
BR (1) BR0111785A (https=)
CA (1) CA2411912C (https=)
DE (1) DE60142786D1 (https=)
WO (1) WO2001097836A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106635849A (zh) * 2016-11-15 2017-05-10 河北工程大学 一种白色念珠菌感染鸡模型建立的方法
CN109069557A (zh) * 2016-03-01 2018-12-21 比欧斯 用于治疗念珠菌感染的组合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146411A (en) * 1998-12-24 2000-11-14 Alsius Corporation Cooling system for indwelling heat exchange catheter
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
CA2577165C (en) * 2004-08-17 2015-01-27 Hunter Immunology Pty Limited Oral killed vaccines and method for providing same
EP1723965A1 (en) 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
WO2009013972A1 (ja) * 2007-07-24 2009-01-29 Dainichiseika Color & Chemicals Mfg. Co., Ltd. 免疫アジュバント及びＩｇＡ抗体測定方法
US9180173B2 (en) * 2013-12-09 2015-11-10 Stephanie D. Neider Methods of treating psoriasis using candida antigen
US11273190B2 (en) * 2019-05-06 2022-03-15 Kenda Rigdon Composition of heat-killed yeast and taurine or a phytomedicine for the treatment of chronic inflammation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2397839A1 (fr) * 1977-07-18 1979-02-16 Grimberg Georges Compose donnant un vaccin oral intestinal
CH680192A5 (https=) * 1989-12-13 1992-07-15 Nestle Sa
JP3510639B2 (ja) * 1991-06-28 2004-03-29 カルピス株式会社 インターロイキン産生能を調節する機能を持たせた機能性食品又は健康食品
GB9417880D0 (en) * 1994-09-06 1994-10-26 Auspharm Int Ltd Vaccine
US5811249A (en) * 1994-10-21 1998-09-22 University Of Utah Research Foundation Control of infectious microorganisms by modulation of chorionic gonadotropin-related protein activity
US5661377A (en) 1995-02-17 1997-08-26 Intraop Medical, Inc. Microwave power control apparatus for linear accelerator using hybrid junctions
JPH09110707A (ja) * 1995-10-12 1997-04-28 Wakamoto Pharmaceut Co Ltd 慢性腎不全改善剤および透析患者のクオリティー オブ ライフ改善剤
US5902578A (en) * 1996-03-25 1999-05-11 Abbott Laboratories Method and formula for the prevention of diarrhea
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
EP0834322A3 (en) * 1996-10-04 1998-04-22 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Mycosis vaccine
JPH10139674A (ja) * 1996-11-11 1998-05-26 Yakult Honsha Co Ltd インターロイキン１２産生促進剤
US5869290A (en) * 1996-11-21 1999-02-09 Smithkline Beecham Corporation Cayae1 polynucleotides
WO1999017788A1 (en) * 1997-10-06 1999-04-15 Abbott Laboratories Composition of treatment of candidiasis
ATE207755T1 (de) * 1998-04-30 2001-11-15 Vesely Renata Maria Cavaliere Pharmazeutische zusammensetzungen enthaltend lactobacillus brevis und lactobacillus salivarius zur behandlung von vaginainfektionen
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069557A (zh) * 2016-03-01 2018-12-21 比欧斯 用于治疗念珠菌感染的组合物
CN106635849A (zh) * 2016-11-15 2017-05-10 河北工程大学 一种白色念珠菌感染鸡模型建立的方法

Also Published As

Publication number Publication date
CN101862449A (zh) 2010-10-20
KR20030016298A (ko) 2003-02-26
WO2001097836A1 (en) 2001-12-27
CA2411912A1 (en) 2001-12-27
EP1303300A1 (en) 2003-04-23
US20040037854A1 (en) 2004-02-26
EP1303300B1 (en) 2010-08-11
ATE476987T1 (de) 2010-08-15
EP1303300A4 (en) 2004-03-24
US7655248B2 (en) 2010-02-02
CA2411912C (en) 2014-06-17
DE60142786D1 (de) 2010-09-23
BR0111785A (pt) 2003-05-20
JP4933714B2 (ja) 2012-05-16
JP2004502653A (ja) 2004-01-29

Similar Documents

Publication Publication Date Title
JP7165218B2 (ja) 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌
Daneshmand et al. Intestinal changes and immune responses during Clostridium perfringens-induced necrotic enteritis in broiler chickens
CN101048168A (zh) 用于改善的阴道健康的益生菌乳杆菌属菌株
CN106659746A (zh) 用于诱导th17细胞的组合物及方法
TW202120109A (zh) 使用普雷沃菌屬治療ｔｈ２介導的病症之組成物及方法
US20190070288A1 (en) Method of inducing tolerance to an allergen
JP2006525313A (ja) 視床下部−脳下垂体−副腎軸過敏性により特徴付けられる非定型うつ病及び他の疾患の治療のプロバイオティック
Zheng et al. The presence of Prevotella melaninogenica within tissue and preliminary study on its role in the pathogenesis of oral lichen planus
Yakoob et al. Cytokine changes in colonic mucosa associated with Blastocystis spp. subtypes 1 and 3 in diarrhoea-predominant irritable bowel syndrome
CN1391480A (zh) 治疗过敏性紊乱的组合物及方法
Gharib-Naseri et al. Differential expression of intestinal genes in necrotic enteritis challenged broiler chickens with 2 different Clostridium perfringens strains
JP2016519126A (ja) バクテリオファージ療法
JP2022133363A (ja) Ｔｈ１細胞を誘導する細菌
EP3237602B1 (en) Method of culturing segmented filamentous bacteria in vitro
CN1443075A (zh) 用于治疗念珠菌病的组合物和方法
EP2879698B1 (fr) Utilisation de souches attenuees de toxoplasma pour la prevention ou le traitement de la cryptosporidiose
CN1760360A (zh) 发酵乳酸杆菌GM－090及其在刺激INF－γ分泌及/或治疗过敏的用途
AU2001265694B2 (en) Compositions and methods for treatment of candidiasis
AU2001265694A1 (en) Compositions and methods for treatment of candidiasis
CN101155596B (zh) 引发抗禽分枝杆菌副结核亚种的免疫应答的组合物
CN101060852A (zh) 口服灭活疫苗及其提供方法
HK1261280B (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
HK1261280A1 (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
BHAUSAHEB EXPRESSION OF IMMUNOMODULATING MARKERS IN MOUSE MODEL BY PROBIOTIC LACTOBACILLUS PLANTARUM 91

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20030917